1-20 of 45
Mika Kontro
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Predictors of Response and Rational Combinations for the Novel MCL-1 Inhibitor MIK665 in Acute Myeloid Leukemia

Joseph Saad, Rhiannon Newman, Elmira Khabusheva, Sofia Aakko, Eric Durand, Mahesh B. Tambe, Heikki Kuusanmäki, Alun Parsons, Juho J. Miettinen, Komal Kumar Javarappa, Nemo Ikonen, Mika Kontro, Kimmo Porkka, Heiko Maacke, Janghee Woo, Ensar Halilovic, Caroline A. Heckman
Journal: Blood
Blood (2024) 144 (Supplement 1): 1560.
https://doi.org/10.1182/blood-2024-207199
Published: 2024
Journal Articles

Comparison of Anti-PD1, Anti-CTLA4 and Anti-TIM3 in Treatment of AML Patients with Single-Cell Transcriptomics Displays Different Effects on Immune Subtypes

Sofia Forstén, Livius Penter, Oscar E. Brück, Johannes Smolander, Karita Peltonen, Harri Lähdesmäki, Mika Kontro, Kimmo Porkka, Hussein A. Abbas, Catherine J. Wu, Jani Huuhtanen, Satu Mustjoki
Journal: Blood
Blood (2024) 144 (Supplement 1): 1529.
https://doi.org/10.1182/blood-2024-199471
Published: 2024
Journal Articles

Encouraging Efficacy of Bexmarilimab with Azacitidine in Relapsed or Refractory MDS in Bexmab Ph1/2 Study

Mika Kontro, Anthony S. Stein, Marja Pyörälä, Johanna Rimpiläinen, Timo Siitonen, Jenna H Rannikko, Jesper Mickos, Rita Turpin, Milja Hakoniemi, Birge Berns, Sofia Aakko, Inka Pawlitzky, Maija Hollmén, Amer M. Zeidan, Naval Daver
Journal: Blood
Blood (2024) 144 (Supplement 1): 4265.
https://doi.org/10.1182/blood-2024-206804
Published: 2024
Journal Articles

Integrating Computational Cytomorphological Analysis of Bone Marrow Smears and Clinical Data for Predicting Response to Venetoclax and Hypomethylating Agents in AML

Henri Sundquist, Mikael Tatun, Mikko Purhonen, Laura Toivanen, Johanna Rimpiläinen, Samuli Rounioja, Timo Siitonen, Marja Pyörälä, Pentti Mäntymaa, Sari Kytölä, Kimmo Porkka, Sanna Siitonen, Heikki Kuusanmäki, Mika Kontro, Oscar E. Brück
Journal: Blood
Blood (2024) 144 (Supplement 1): 4320.
https://doi.org/10.1182/blood-2024-206949
Published: 2024
Journal Articles

Integrative Analysis of Transcriptomic and Proteomic Data Identifies Patterns of Primary Resistance to Venetoclax-Azacitidine and Reveals Targetable Vulnerabilities in Acute Myeloid Leukemia (AML)

Ida Vänttinen, Joseph Saad, Tanja Ruokoranta, Sari Kytölä, Pia-Sofia Ettala, Marja Pyörälä, Johanna Rimpiläinen, Timo Siitonen, Caroline A. Heckman, Heikki Kuusanmäki, Mika Kontro
Journal: Blood
Blood (2024) 144 (Supplement 1): 2757.
https://doi.org/10.1182/blood-2024-209429
Published: 2024
Journal Articles

Ex Vivo Venetoclax Sensitivity Predicts Clinical Response in Acute Myeloid Leukemia in the Prospective VenEx Trial

Clinical Trials & Observations
Sari Kytölä, Ida Maria Vänttinen, Tanja Ruokoranta, Anu Partanen, Annasofia Holopainen, Joseph Saad, Milla E.L. Kuusisto, Sirpa Koskela, Riikka Katariina Räty, Maija Itälä-Remes, Imre Västrik, Minna Suvela, Alun Owen Parsons, Kimmo Porkka, Krister Wennerberg, Caroline A. Heckman, Tero Jalkanen, Teppo Huttunen, Pia Ettala, MD, Johanna Rimpiläinen, Timo Siitonen, Marja Pyörälä, Heikki Kuusanmäki, Mika Kontro
Journal: Blood
Blood blood.2024024968.
https://doi.org/10.1182/blood.2024024968
Published: 2024
Includes: Supplemental data
Journal Articles

Targeting Venetoclax Resistance in TP53 -Mutated Acute Myeloid Leukemia

Ida Vänttinen, Tanja Ruokoranta, Joseph J Saad, Sari Kytölä, Monica Hellesøy, Stein-Erik Gullaksen, Pia-Sofia Ettala, Marja Pyörälä, Johanna Rimpiläinen, Timo Siitonen, Krister Wennerberg, Bjorn T. Gjertsen, Caroline A. Heckman, Mika Kontro, Heikki Kuusanmäki
Journal: Blood
Blood (2023) 142 (Supplement 1): 2927.
https://doi.org/10.1182/blood-2023-189340
Published: 2023
Journal Articles

Encouraging Efficacy Observed in Bexmab Study: A Phase 1/2 Study to Assess Safety and Efficacy of Bexmarilimab in Combination with Standard of Care in Myeloid Malignancies

Mika Kontro, Anthony Selwyn Stein, Marja Pyörälä, Johanna Rimpiläinen, Timo Siitonen, Maija Hollmén, Marie-Louise Fjaellskog, Inka Pawlitzky, Amer M. Zeidan, Naval Daver
Journal: Blood
Blood (2023) 142 (Supplement 1): 2915.
https://doi.org/10.1182/blood-2023-174912
Published: 2023
Journal Articles

Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia

Heikki Kuusanmäki, Olli Dufva, Markus Vähä-Koskela, Aino-Maija Leppä, Jani Huuhtanen, Ida Vänttinen, Petra Nygren, Jay Klievink, Jonas Bouhlal, Petri Pölönen, Qi Zhang, Shady Adnan-Awad, Cristina Mancebo-Pérez, Joseph Saad, Juho Miettinen, Komal K. Javarappa, Sofia Aakko, Tanja Ruokoranta, Samuli Eldfors, Merja Heinäniemi, Kim Theilgaard-Mönch, Ulla Wartiovaara-Kautto, Mikko Keränen, Kimmo Porkka, Marina Konopleva, Krister Wennerberg, Mika Kontro, Caroline A. Heckman, Satu Mustjoki
Journal: Blood
Blood (2023) 141 (13): 1610–1625.
https://doi.org/10.1182/blood.2021011094
Published: 2023
Includes: Supplemental data
Journal Articles

Erythroid/Megakaryocytic Differentiation Confers BCL-XL Dependency and Venetoclax Resistance in Acute Myeloid Leukemia

Olli Dufva, Heikki Kuusanmäki, Markus Vaha-Koskela, Aino-Maija Leppä, Jani Huuhtanen, Ida Vänttinen, Petra Johanna Nygren, Jay Klievink, Jonas Bouhlal, Petri Pölönen, Qi Zhang, Shady Adnan Awad, Cristina Mancebo, Joseph Saad, Juho J. Miettinen, Komal Kumar Javarappa, Sofia Aakko, Tanja Ruokoranta, Samuli Eldfors, Merja Heinäniemi, Ulla Wartiovaara-Kautto, Marina Konopleva, Mikko A Keränen, Kimmo Porkka, Krister Wennerberg, Mika Kontro, Caroline A. Heckman, Satu Mustjoki
Journal: Blood
Blood (2022) 140 (Supplement 1): 101–103.
https://doi.org/10.1182/blood-2022-158694
Published: 2022
Journal Articles

Trial in Progress: A Phase I/II Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination with Standard of Care in Patients with Hematological Malignancies (BEXMAB)

Inka Pawlitzky, Timo Siitonen, Naval Daver, Juho Jalkanen, Sofia Aako, Marie-Louise Fjällskog, Mika Kontro
Journal: Blood
Blood (2022) 140 (Supplement 1): 11751–11752.
https://doi.org/10.1182/blood-2022-156786
Published: 2022
Journal Articles

Ex Vivo Venetoclax Sensitivity Testing Predicts Response and Overall Survival in De Novo and s/R/R AML Patients Treated with Azacitidine and Venetoclax

Sari Kytölä, Ida Vänttinen, Tanja Ruokoranta, Annasofia Holopainen, Anu Partanen, Milla E.L. Kuusisto, Sirpa Koskela, Riikka Räty, Maija Itälä-Remes, Amanda Ranta, Minna Suvela, Alun Parsons, Imre Västrik, Sanna M. Siitonen, Kimmo Porkka, Krister Wennerberg, Caroline A. Heckman, Pia Ettala, Johanna Rimpiläinen, Timo Siitonen, Marja Pyörälä, Heikki Kuusanmäki, Mika Kontro
Journal: Blood
Blood (2022) 140 (Supplement 1): 2020–2022.
https://doi.org/10.1182/blood-2022-159391
Published: 2022
Journal Articles

Monosomy 7 and Del(7q) Cause Selective Sensitivity to Inhibitors of Nicotinamide Phosphoribosyltransferase in Acute Myeloid Leukemia

Joseph Saad, Samuli Eldfors, Vilma Ikonen, Bjørn Tore Gjertsen, Mika Kontro, Kimmo Porkka, Caroline A. Heckman
Journal: Blood
Blood (2022) 140 (Supplement 1): 1033–1035.
https://doi.org/10.1182/blood-2022-163242
Published: 2022
Journal Articles

Allogeneic Hematopoietic Cell Transplantation Outcomes of Patients with R/R AML or Higher-Risk MDS Treated with the TIM-3 Inhibitor MBG453 (Sabatolimab) and Hypomethylating Agents

Andrew M. Brunner, Elie Traer, Norbert Vey, Sebastian Scholl, Natalia Tovar, Kimmo Porkka, Rupa Narayan, Guillermo Garcia-Manero, Steve Knapper, Martin Wermke, Jeroen J. Janssen, Jordi Esteve, Sun Loo, Mika Kontro, Zachariah Defilipp, Andrew H. Wei, Uma Borate
Journal: Blood
Blood (2021) 138 (Supplement 1): 3677.
https://doi.org/10.1182/blood-2021-151455
Published: 2021
Journal Articles

Ex Vivo Drug Sensitivity Testing to Predict Response to Venetoclax + Azacitidine in Acute Myeloid Leukemia: Interim Results of the Prospective Multicenter Phase II Venex Trial

Heikki Kuusanmäki, Sari Kytölä, Ida Vänttinen, Amanda Ranta, Tanja Ruokoranta, Annasofia Holopainen, Sirpa Koskela, Milla E.L. Kuusisto, Kimmo Porkka, Riikka Räty, Imre Västrik, Krister Wennerberg, Caroline A. Heckman, Pia Ettala, Marja Pyörälä, Johanna Rimpiläinen, Timo Siitonen, Mika Kontro
Journal: Blood
Blood (2021) 138 (Supplement 1): 228.
https://doi.org/10.1182/blood-2021-147691
Published: 2021
Journal Articles

Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients (Pts) with Very High/High-Risk Myelodysplastic Syndrome (vHR/HR-MDS) and Acute Myeloid Leukemia (AML): Final Analysis from a Phase Ib Study

Andrew M. Brunner, Jordi Esteve, Kimmo Porkka, Steve Knapper, Elie Traer, Sebastian Scholl, Guillermo Garcia-Manero, Norbert Vey, Martin Wermke, Jeroen Janssen, Rupa Narayan, Sun Loo, Mika Kontro, Oliver Ottmann, Purushotham Naidu, Marc Pelletier, May Han, Andrew Lewandowski, Na Zhang, Anisa Mohammed, Mikael L. Rinne, Uma Borate, Andrew H. Wei, Natalia Tovar
Journal: Blood
Blood (2021) 138 (Supplement 1): 244.
https://doi.org/10.1182/blood-2021-146039
Published: 2021
Journal Articles

Single-Cell Characterization of the Immune and Leukemic Cells Following Anti-TIM3 and Hypomethylating Agent Combination Therapy in Patients with AML or MDS

Jani Huuhtanen, Oscar Brück, Karita Peltonen, Anna Kreutzman, Olli Dufva, Matti Kankainen, Mette Ilander, Hanna Lähteenmäki, Tiina Kasanen, Jay Klievink, Mika Kontro, Elena J Orlando, Viviana Cremasco, Joel Wagner, Marc Pelletier, Harri Lähdesmäki, Catherine A. Sabatos-Peyton, Mikael L. Rinne, Kimmo Porkka, Satu Mustjoki
Journal: Blood
Blood (2021) 138 (Supplement 1): 801.
https://doi.org/10.1182/blood-2021-147150
Published: 2021
Journal Articles

Sabatolimab (MBG453) Dose Selection and Dose-Response Analysis in Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML): Population Pharmacokinetics (PK) Modeling and Evaluation of Clinical Efficacy/Safety By Dose

Andrew H. Wei, MBBS, PhD, Jordi Esteve, Kimmo Porkka, Steve Knapper, Norbert Vey, MD, Sebastian Scholl, Guillermo Garcia-Manero, MD, Martin Wermke, Jeroen Janssen, Elie Traer, Sun Loo, Rupa Narayan, Natalia Tovar, Mika Kontro, Oliver Ottmann, Siyan Xu, Serena Liao, Andrew Stein, Fariba Khanshan, Purushotham Naidu, Na Zhang, Anisa Mohammed, Mikael L. Rinne, Haiying Sun, Andrew M. Brunner, MD, Uma Borate
Journal: Blood
Blood (2020) 136 (Supplement 1): 40–42.
https://doi.org/10.1182/blood-2020-137307
Published: 2020
Journal Articles

Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study

Andrew M. Brunner, MD, Jordi Esteve, Kimmo Porkka, Steve Knapper, Norbert Vey, MD, Sebastian Scholl, Guillermo Garcia-Manero, MD, Martin Wermke, Jeroen Janssen, Elie Traer, Sun Loo, Rupa Narayan, Natalia Tovar, Mika Kontro, Oliver Ottmann, Purushotham Naidu, Sema Kurtulus, Jessica Makofske, Serena Liao, Anisa Mohammed, Catherine A. Sabatos-Peyton, Mikael L. Rinne, Uma Borate, Andrew H. Wei, MBBS, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 1–2.
https://doi.org/10.1182/blood-2020-136855
Published: 2020
Journal Articles

Phase Ib Study of the Anti-TIM-3 Antibody MBG453 in Combination with Decitabine in Patients with High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Uma Borate, MD, Jordi Esteve, Kimmo Porkka, Steve Knapper, Norbert Vey, MD PhD, Sebastian Scholl, Guillermo Garcia-Manero, MD, Martin Wermke, MD, Jeroen Janssen, Elie Traer, Chong Chyn Chua, Rupa Narayan, Natalia Tovar, Mika Kontro, Oliver Ottmann, Prof, MD, Haiying Sun, Tyler Longmire, Sebastian Szpakowski, Serena Liao, Anuradha Patel, Mikael L Rinne, Andrew Brunner, MD, Andrew H. Wei, PhD FRACP, FRCPA, MBBS
Journal: Blood
Blood (2019) 134 (Supplement_1): 570.
https://doi.org/10.1182/blood-2019-128178
Published: 2019